38 research outputs found

    Roman hospital management of a potential CBRNE event

    No full text
    Background: Rome hosts 6 advanced Emergency Departments (EDs) and 7 basic ones are the first line of defense of the city, and should provide healthcare assistance in case of maxi-emergencies. Rome hosts 5 warehouses of National Stockpile Antidotes (SNA), in case of a CBRN event, stockpiles are activated with a long-time call to be charged and delivered through specific trucks. Methods: The present study analyzes the PEIMAFs (State of emergency plans for massive influx of injures) of advanced EDs in Rome and their adequacy in case of a CBRNe attack. We hypothesized a chemical attack at Saint Peter’s Square during the General Assembly, on Wednesday (at 12.00).Subsequently, with a table-top simulation we evaluated the efficacy and the effectiveness of the SNA, and the travel times between the SNA warehouse and EDs. Findings: Being EDs chronically undermanned during the ordinary working conditions there will be serious issues in suddenly hosting a very large number of critical patients. In addition not all the hospitals inform their workers about PEIMAF or consider CBRNe emergencies in their PEIMAF, and simulations are not always performed. Moreover, the communication between the different institution involved is not optimal, presenting a major risk of contamination in case of CBRNe attacks. Conclusions: Our data highlight that despite an overall good organization there is room of improvement in shorting the times of travelling. In addition we believe is mandatory to develop in all the major roman hospitals the PEIMAF, which should be followed strictly by an organized training plan involving both theorical teaching, indoor and outdoor simulation, in order to train the hospital personnel and to evaluate weaknesses and vulnerabilities of the single PEIMAFs. Concluding, a smart call system can reduce the activation time of SNA, as well as well a better organization between the major hospitals in Rome, which can help reducing delivering time

    Focal nodular hyperplasia and hepatic regenerating nodules in pediatric oncology patients: how much invasive approach is necessary?

    Get PDF
    Introduction. Hepatic regenerating nodules (HRN) and focal nodular hyperplasia (FNH) are benign regenerating lesions of the liver that rarely occur in children. An increased incidence of these lesions is reported in children treated for cancer.Material and methods. Eight children who developed FNH and HRN after treatment for malignancies in the Oncology unit at the “Bambino Gesu” Pediatric Hospital in Rome, were retrospectively analyzed.Results. The lesions, considered in the differential diagnosis with metastatic relapse of the primitive disease, have been monitored with US or other available imaging techniques. Evolution of the lesions was observed in only 1 patient three years after the initial diagnosis of FNH.Conclusion. In conclusion serial monitoring with imaging techniques is sufficient to rule out liver metastasis and to monitor the evolution of the lesions. Surgery is suggested only in the case of complications

    Cobalamin c defect presenting with isolated pulmonary hypertension

    No full text
    Cobalamin C (cblC) defect is the most common inborn error of vitamin B-12 metabolism. Clinical features vary as does the severity of the disease. In most cases, the clinical symptoms of cblC defect tend to appear during infancy or early childhood as a multisystem disease with severe neurologic, ocular, hematologic, renal, and gastrointestinal signs. The neurologic findings are common and include hypotonia, developmental delay, microcephaly, seizures hydrocephalus, and brain MRI abnormalities. We report a case of a young boy with cblC defect, who did not undergo newborn screening, presenting at the age of 2 years with isolated pulmonary hypertension as the leading symptom. This novel way of presentation of cblC defect enlarges the spectrum of inherited diseases that must be considered in the differential diagnosis of pulmonary hypertension

    lomeprol versus iopamidol in tomography of thoracic contrast-enhanced computed and abdominal organs

    No full text
    The aim of this double-blind, parallel-group study was to compare the safety, tolerance, and elficacy ol iomeprol-350 (350 mgl/ml), iomeprol-400 (400 mgl/ml) and iopamidol-37O (370 mgl/ml) for use in contrast-enhanced body computed tomography (CT). Following written informed consent, 120 adult inpatients of either sex requiring CT of thoracic or abdominal organs were randomly assigned to receive iomeprol-350, iomeprol-400 or iopamidol-370. Pre- and post-contrast, all patients underwent clinical, instrumental and laboratory investigation to assess the salety olthe test agents. Tolerance was assessed in terms of discomfort associated with contrast injection. Two experienced radiologists independently and blindly graded the quality ol contrast enhancement obtained with the different contrast solutions by means ola five-point ordinal scale as follows: 1, insufficient;2, sufficient; 3, good; 4, excellent; or E, excessive. Patients in the iomeprol groups needed lewer injections and a smaller volume of contrast medium to obtain examinations of adequate diagnostic quality. Contrast enhancement was judged as excellent or good in about 90% ofthe study examinations, without significant differences between the three study groups. During contrast injection, heat and pain sensations were minimal or absent in most cases. No serious adverse events occurred throughout the study. No significant changes in clinical, instrumental or laboratory safety parameters were observed. In conclusion, iomeprol-4O0 and iomeprol-350 appear to be contrast solutions at least as sale, well tolerated and effective as iopamidol-370 when used as contrast agents lor body CT

    Extrahepatic portal vein thrombosis in children and adolescents: Influence of genetic thrombophilic disorders

    No full text
    AIM: To explore the prevalence of local and genetic thrombophilic disorders as risk factors for portal vein thrombosis (PVT) in our series, the largest ever published in pediatric literature

    Recommendations for the management of tyrosinaemia type 1.

    Get PDF
    The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies.The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.SCOPUS: re.jinfo:eu-repo/semantics/publishe
    corecore